New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumors
A Ludwig Cancer Research study shows that ovarian cancer, which has proved resistant to currently available immunotherapies, could be susceptible to personalized immunotherapy. Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that ovarian tumors harbor highly reactive killer T cells—which kill infected and cancerous cells—and demonstrates how they can be identified and selectively grown for use in personalized, cell-based immunotherapies.
“Tumors whose cells tend to be highly mutated, like those of melanoma and lung cancer, are the ones that respond best to immunotherapies,” says Harari. “It has long been a question whether we’d even be able to detect sufficiently mutation-reactive T cells in patients with tumors that have low mutational loads.”
Harari, Coukos and their colleagues report in Nature Communicationsthat, despite their low mutational load, epithelial ovarian tumors are infiltrated with T cells that are especially good at recognizing and killing cancer cells.
Cancer cells that have a relatively large number of mutations in their DNA express aberrant proteins—or neoantigens—that reveal the cancer to the immune system. Killer T cells recognize tiny, mutated bits of these antigens, known as neoepitopes. But neoepitopes vary wildly from patient to patient, even within the same type of cancer. This has long stymied efforts to develop generally effective therapies that target cancer antigens.
To get around this problem, researchers have been developing sophisticated methods to extract T cells from patients, select and expand those that best target a patient’s cancer and reinfuse them into the patient. These approaches usually rely on T cells extracted from the bloodstream, not those already inside the tumor, which are referred to as TILs (for tumor infiltrating lymphocytes).
Experimental therapies using T cells taken from the blood stream have not, however, worked very well against solid tumors. Further, when TILs have been used for such purposes, the proportion of what Harari calls the “juiciest” T cells—those recognizing mutations on cancer cells—tends to decline significantly when the cells are expanded in culture.
“To circumvent these problems, we developed a new methodology to identify highly reactive TILs and expand them in a manner that, rather than diluting the juiciest TILs, enriches them instead,” says Harari. “This allowed us to compare the activity of TILs that target neoepitopes with their counterparts in the peripheral bloodstream.”
The researchers show that killer T cells isolated from ovarian tumors using their method are much better at both recognizing neoepitopes than are those isolated from blood.
“We could even compare T cells from the two compartments targeting the exact same mutation and show that the TILs were more functional than the T cells we collected from the peripheral bloodstream,” says Harari.
Notably, the researchers found that, using their methods, highly reactive TILs could be obtained from some 90% of the ovarian cancer patients whose tumor samples they examined.
“The big message,” says Coukos, “is that future cell-based therapies can be envisioned for low mutational load tumors and should prioritize the use of TILs over T cells collected from peripheral blood. This novel strategy to obtain enriched TILs also offers great therapeutic opportunities.”
Harari, Coukos and their colleagues will now be applying their findings to an ambitious program to develop and streamline personalized immunotherapies for cancer patients currently underway at the Lausanne Branch of the Ludwig Institute for Cancer Research.
Learn more: LUDWIG STUDY EXTENDS THE POTENTIAL FOR PERSONALIZED IMMUNOTHERAPY TO A LARGE VARIETY OF CANCERS
The Latest on: Personalized cell-based immunotherapies
[google_news title=”” keyword=”personalized cell-based immunotherapies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized cell-based immunotherapies
- Giving Hope: All about the world's first personalised melanoma vaccine tested in the UKon April 26, 2024 at 5:34 am
The world’s first-ever personalised mRNA vaccine for melanoma is being tested on British patients. It is a custom-built jab for people created using the specific genetic makeup of their tumour ...
- Cancer Newson April 25, 2024 at 5:00 pm
Tumor Cells Evade the Immune System Early On: Newly Discovered Mechanism Could Significantly Improve Cancer Immunotherapies ... New Urine-Based Test Detects High-Grade Prostate Cancer, Helping ...
- British patients test world’s first personalised MRNA cancer jab for melanomaon April 25, 2024 at 4:10 pm
The ‘gamechanger’ jab works by telling the body to hunt down cancer cells and prevent the deadly disease from coming back ...
- New device improves stem cell generation and chance for accessible Alzheimer's cell therapyon April 24, 2024 at 12:11 pm
Researchers in Sweden say they have improved on a technique for converting regular skin cells into neural stem cells—an advance that they say helps close the gap for accessible personalized cell-based ...
- MobileX Uses AI for Personalized Cellphone Plans, from $4.08 Per Monthon April 19, 2024 at 10:57 am
What sets it apart is that its app-based service leverages AI to provide consumers with hyper-personalized service to fit an array of budgets and data uses. MobileX can be activated with either a ...
- FDA Calls for Boxed Warnings for CAR T-Cell Immunotherapieson April 19, 2024 at 7:15 am
Following an investigation that began in November 2023, the FDA now requires boxed warnings regarding T-cell malignancies on all BCMA- and CD19-directed T-cell products.
- AACR 2024: Geneos Therapeutics’ Vaccine Outperforms Liver Cancer Immunotherapieson April 8, 2024 at 5:00 pm
Sardesai is doing this at Geneos, a clinical-stage biotherapeutics company focused on developing DNA-based personalized ... and without T cells, immunotherapies do not work. Even if the PTCV ...
- AI Tool Predicts Immune Responses in Fight Against Canceron March 30, 2024 at 12:14 am
Spearheaded by ASU scientists, the team’s groundbreaking AI-based ... to foreign cells. This revolutionary tool holds immense potential to predict immune responses, revolutionize personalized ...
- Researchers develop AI-based tool paving the way for personalized cancer treatmentson March 29, 2024 at 8:21 am
The work was published in the journal of Cell Systems ... Next-generation immunotherapies will be highly precise and tailored based on an individual's MHC molecules." The researchers envision ...
via Bing News